Advertisement
Canada markets closed
  • S&P/TSX

    21,875.79
    -66.37 (-0.30%)
     
  • S&P 500

    5,460.48
    -22.39 (-0.41%)
     
  • DOW

    39,118.86
    -45.20 (-0.12%)
     
  • CAD/USD

    0.7312
    +0.0011 (+0.15%)
     
  • CRUDE OIL

    81.46
    -0.28 (-0.34%)
     
  • Bitcoin CAD

    83,280.80
    +185.79 (+0.22%)
     
  • CMC Crypto 200

    1,262.88
    -20.95 (-1.63%)
     
  • GOLD FUTURES

    2,336.90
    +0.30 (+0.01%)
     
  • RUSSELL 2000

    2,047.69
    +9.35 (+0.46%)
     
  • 10-Yr Bond

    4.3430
    +0.0550 (+1.28%)
     
  • NASDAQ

    17,732.60
    -126.08 (-0.71%)
     
  • VOLATILITY

    12.44
    +0.20 (+1.63%)
     
  • FTSE

    8,164.12
    -15.56 (-0.19%)
     
  • NIKKEI 225

    39,583.08
    +241.54 (+0.61%)
     
  • CAD/EUR

    0.6820
    +0.0003 (+0.04%)
     

Gilead’s Twice-Yearly Shot Prevents HIV. Where the Stock Is Headed.

Gilead’s Twice-Yearly Shot Prevents HIV. Where the Stock Is Headed.

There were zero HIV cases among the 2,124 test subjects who received the antiviral injection called lenacapavir.